R.H. Bluestein & Co’s CRISPR Therapeutics CRSP Stock Holding History

R.H. Bluestein & Co’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$372K	Sell	5,700 -150	-3%	-$10.9K	0.02%	191
2022 Q2	$356K	Sell	5,850 -10	-0.2%	-$588	0.02%	209
2022 Q1	$368K	Sell	5,860 -415	-7%	-$26.1K	0.02%	252
2021 Q4	$476K	Sell	6,275 -1,000	-14%	-$87.4K	0.02%	221
2021 Q3	$814K	Sell	7,275 -4,750	-40%	-$597K	0.03%	140
2021 Q2	$1.95M	Buy	12,025 +4,575	+61%	+$556K	0.08%	72
2021 Q1	$908K	Buy	7,450 +900	+14%	+$136K	0.04%	112
2020 Q4	$1M	Buy	6,550 +850	+15%	+$100K	0.04%	101
2020 Q3	$477K	Sell	5,700 -300	-5%	-$26.6K	0.02%	166
2020 Q2	$441K	Sell	6,000 -75,642	-93%	-$4.42M	0.02%	165
2020 Q1	$3.46M	Buy	81,642 +71,142	+678%	+$3.67M	0.29%	50
2019 Q4	$640K	Buy	10,500 +3,400	+48%	+$186K	0.03%	129
2019 Q3	$291K	Sell	7,100 -400	-5%	-$19.1K	0.02%	255
2019 Q2	$353K	Buy	+7,500	New	+$300K	0.02%	197

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

R.H. Bluestein & Co's CRSP Position: Q3 2022 in Review

R.H. Bluestein & Co reduced its CRISPR Therapeutics (CRSP) stake by 2.6% in Q3 2022, selling an estimated $10.9K and leaving 5,700 shares worth $372K. The position accounts for 0.02% of the portfolio, ranked #191.

R.H. Bluestein & Co first reported a position in CRSP in Q2 2019 and has held it in 14 quarters since. The position peaked at $3.46M in Q1 2020. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

R.H. Bluestein & Co held 5,700 shares of CRISPR Therapeutics worth $372K as of Q3 2022.
R.H. Bluestein & Co sold 150 CRISPR Therapeutics shares in Q3 2022, an estimated $10.9K.
CRISPR Therapeutics made up 0.02% of R.H. Bluestein & Co's portfolio in Q3 2022, its #191 holding.
R.H. Bluestein & Co first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 14 quarters since.
R.H. Bluestein & Co's CRISPR Therapeutics position peaked at $3.46M in Q1 2020.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.